Ironwood Pharmaceuticals Inc. (IRWD) financial statements: income statement, balance sheet and cash flow
Ironwood Pharmaceuticals Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Ironwood Pharmaceuticals Inc. reported revenue of $296.2M (-15.7% year on year) and net income of $24.0M (+2629.2% year on year).
Income statement
Ironwood Pharmaceuticals Inc. income statement, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Total revenues
$296.2M
$351.4M
$442.7M
$410.6M
Research and development
$95.1M
$111.4M
$116.1M
$44.3M
Selling, general and administrative
$82.3M
$144.3M
$158.3M
$116.0M
Restructuring, net
$20.3M
$2.6M
$18.3M
—
Total costs and expenses
$197.6M
$258.3M
$1.4B
$160.3M
Income from operations
$98.5M
$93.1M
($945.4M)
$250.3M
Interest expense and other financing costs
($32.7M)
($33.0M)
($21.6M)
—
Interest and investment income
$4.1M
$4.5M
$19.0M
$9.5M
Other
$193.0K
$640.0K
—
—
Other income (expense), net
($28.5M)
($27.9M)
($2.6M)
$2.1M
Income before income taxes
$70.0M
$65.2M
($948.1M)
$252.4M
Income tax expense
($46.0M)
($64.3M)
($83.5M)
($77.4M)
Net income
$24.0M
$880.0K
($1.0B)
$175.1M
Net income per share - basic (in dollars per share)
$0.15
$0.01
-$6.45
$1.13
Net income per share - diluted (in dollars per share)
$0.15
$0.01
-$6.45
$0.96
Weighted average shares used in computing net income per share - basic (in shares)
$161842000.00
$159083000.00
$155435000.00
$154366000.00
Weighted average shares used in computing net income per share - diluted (in shares)
$162983000.00
$160084000.00
$155435000.00
$186312000.00
Ironwood Pharmaceuticals Inc. income statement, quarters
Line item
Jun 30, 2026 · Q2
Mar 31, 2026 · Q1
Sep 30, 2025 · Q3
Jun 30, 2025 · Q2
Total revenues
$113.0M
$106.5M
$122.1M
$85.2M
Research and development
$22.4M
$21.9M
$22.5M
$23.4M
Selling, general and administrative
$11.3M
$12.0M
$21.9M
$16.8M
Total costs and expenses
$33.7M
$33.9M
$46.6M
$39.9M
Income from operations
$79.3M
$72.6M
$75.5M
$45.3M
Interest expense and other financing costs
($7.2M)
($9.1M)
($8.4M)
($8.4M)
Interest and investment income
$1.6M
$1.7M
$930.0K
$818.0K
Other
$42.0K
$42.0K
$40.0K
$39.0K
Other income (expense), net
($5.6M)
($7.4M)
($7.5M)
($7.5M)
Income before income taxes
$73.7M
$65.2M
$68.0M
$37.8M
Income tax expense
($22.4M)
($24.4M)
($27.9M)
($14.2M)
Net income (loss)
$51.3M
$40.8M
$40.1M
$23.6M
Net income (loss) per share - basic (in dollars per share)
$0.31
$0.25
$0.25
$0.15
Net income (loss) per share - diluted (in dollars per share)
$0.31
$0.24
$0.23
$0.14
Weighted average shares used in computing net income (loss) per share - basic (in shares)
$164405000.00
$163451000.00
$162215000.00
$161723000.00
Weighted average shares used in computing net income (loss) per share - diluted (in shares)
$167179000.00
$166690000.00
$177764000.00
$176837000.00
Balance sheet
Ironwood Pharmaceuticals Inc. balance sheet, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Cash and cash equivalents
$215.5M
$88.6M
$92.2M
$656.2M
Accounts receivable, net
$46.7M
$81.9M
$129.1M
$115.5M
Prepaid expenses and other current assets
$12.0M
$11.9M
$12.0M
$7.7M
Total current assets
$274.2M
$182.4M
$233.3M
$780.6M
Property and equipment, net
$3.4M
$4.5M
$5.6M
$6.3M
Operating lease right-of-use assets
$9.3M
$11.0M
$12.6M
$14.0M
Intangible assets, net
$2.0M
$2.9M
$3.7M
—
Deferred tax assets
$103.4M
$144.2M
$212.3M
$283.7M
Other assets
$4.5M
$5.9M
$3.6M
$847.0K
Total assets
$396.9M
$350.9M
$471.1M
$1.1B
Accounts payable
$2.9M
$2.1M
$7.8M
$483.0K
Accrued research and development costs
$3.1M
$6.7M
$21.3M
$5.3M
Accrued expenses and other current liabilities
$33.2M
$26.8M
$44.3M
$16.7M
Current portion of operating lease liabilities
$3.3M
$3.2M
$3.1M
$3.1M
Current portion of convertible senior notes
$199.7M
—
$199.6M
—
Total current liabilities
$242.2M
$38.8M
$276.1M
$25.5M
Operating lease obligations, net of current portion
$9.9M
$12.3M
$14.5M
$16.6M
Revolving credit facility
$385.0M
$385.0M
$300.0M
—
Other liabilities
$21.6M
$17.1M
$28.4M
$9.8M
Class A Common Stock, $0.001 par value, 500,000,000 shares authorized and 163,058,316 shares issued and outstanding as of December 31, 2025 and 500,000,000 shares authorized and 160,205,899 shares issued and outstanding as of December 31, 2024
163.0K
160.0K
156.0K
154.0K
Additional paid-in capital
$1.4B
$1.4B
$1.4B
$1.3B
Accumulated deficit
($1.7B)
($1.7B)
($1.7B)
($696.4M)
Accumulated other comprehensive income (loss)
($1.1M)
$923.0K
($3.0M)
—
Total stockholders' deficit
($261.8M)
($301.3M)
($346.3M)
$652.4M
Total liabilities and stockholders' deficit
$396.9M
$350.9M
$471.1M
$1.1B
Ironwood Pharmaceuticals Inc. balance sheet, quarters
Line item
Jun 30, 2026
Mar 31, 2026
Sep 30, 2025
Jun 30, 2025
Cash and cash equivalents
$79.1M
$220.5M
$140.4M
$92.9M
Accounts receivable, net
$112.7M
$105.8M
$120.4M
$86.2M
Prepaid expenses and other current assets
$7.3M
$6.0M
$13.1M
$12.7M
Total current assets
$199.2M
$332.3M
$273.8M
$191.8M
Property and equipment, net
$2.9M
$3.2M
$3.7M
$3.9M
Operating lease right-of-use assets
$8.4M
$8.9M
$9.8M
$10.2M
Intangible assets, net
$1.6M
$1.8M
$2.2M
$2.5M
Deferred tax assets
$69.1M
$84.2M
$101.7M
$129.5M
Other assets
$3.9M
$4.1M
$4.8M
$5.2M
Total assets
$285.1M
$434.6M
$396.1M
$342.9M
Accounts payable
$911.0K
$3.2M
$1.6M
$1.4M
Accrued research and development costs
$3.1M
$2.0M
$3.5M
$4.6M
Accrued expenses and other current liabilities
$25.5M
$27.9M
$34.6M
$24.0M
Current portion of operating lease liabilities
$3.3M
$3.3M
$3.2M
$3.2M
Total current liabilities
$32.9M
$236.3M
$242.5M
$232.5M
Operating lease obligations, net of current portion
$8.6M
$9.2M
$10.5M
$11.1M
Revolving credit facility
$385.0M
$385.0M
$385.0M
$385.0M
Other liabilities
$20.5M
$21.2M
$22.2M
$22.5M
Total liabilities
$447.0M
—
—
—
Class A Common Stock, $0.001 par value, 500,000,000 shares authorized; 165,239,947 shares issued and outstanding as of June 30, 2026 and 163,058,316 shares issued and outstanding as of December 31, 2025
165.0K
165.0K
163.0K
162.0K
Additional paid-in capital
$1.4B
$1.4B
$1.4B
$1.4B
Accumulated deficit
($1.6B)
($1.6B)
($1.7B)
($1.7B)
Accumulated other comprehensive loss
($324.0K)
($795.0K)
($1.7M)
($2.0M)
Total stockholders' deficit
($161.8M)
($217.1M)
($264.2M)
($308.2M)
Total liabilities and stockholders' deficit
$285.1M
$434.6M
$396.1M
$342.9M
Cash flow statement
Ironwood Pharmaceuticals Inc. cash flow statement, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Net income
$24.0M
$880.0K
($1.0B)
$175.1M
Depreciation and amortization
$1.9M
$2.0M
$1.6M
$1.4M
Loss on disposal of property and equipment
$89.0K
$75.0K
—
$2.0K
Share-based compensation expense
$17.3M
$29.9M
$32.0M
$27.0M
Non-cash interest expense
$1.7M
$1.9M
$2.1M
$1.9M
Non-cash lease expense
$1.7M
—
—
—
Deferred income taxes
$40.8M
$68.1M
$72.6M
$65.7M
Accounts receivable, net
$35.1M
$47.2M
$924.0K
—
Prepaid expenses and other current assets
$367.0K
$89.0K
$4.2M
$3.2M
Other assets
$447.0K
($854.0K)
($319.0K)
$153.0K
Accounts payable and accrued expenses
$6.2M
($20.2M)
$12.4M
($8.1M)
Accrued research and development costs
($4.1M)
($14.7M)
($5.9M)
($10.6M)
Operating lease liabilities
($2.4M)
($2.2M)
($2.0M)
($1.9M)
Other liabilities
$4.0M
($10.3M)
$507.0K
$10.8M
Net cash provided by operating activities
$127.0M
$103.5M
$183.4M
$273.8M
Purchases of property and equipment
($34.0K)
($142.0K)
($273.0K)
($136.0K)
Net cash used in investing activities
($34.0K)
($142.0K)
($1.0B)
($136.0K)
Proceeds from exercise of stock options and employee stock purchase plan
216.0K
11.0M
6.4M
9.5M
Net cash provided by (used in) financing activities
$216.0K
($107.0M)
$277.2M
($237.6M)
Effect of exchange rate changes on cash and cash equivalents
($329.0K)
($32.0K)
($53.0K)
—
Net increase (decrease) in cash and cash equivalents
$126.9M
($3.6M)
($565.8M)
$36.1M
Cash and cash equivalents, beginning of period
$88.6M
$92.2M
$657.9M
$621.9M
Cash and cash equivalents, end of period
$215.5M
—
—
—
Cash paid for interest
$30.3M
$32.6M
$13.6M
$5.7M
Cash paid for income taxes
$3.5M
$8.4M
$9.9M
$4.6M
Ironwood Pharmaceuticals Inc. cash flow statement, quarters
Line item
Jun 30, 2026 · YTD
Mar 31, 2026 · Q1
Sep 30, 2025 · YTD
Jun 30, 2025 · YTD
Net income (loss)
$92.1M
$40.8M
$26.3M
($13.8M)
Depreciation and amortization
$900.0K
$443.0K
$1.4M
$946.0K
Share-based compensation expense
$6.9M
$3.7M
$13.4M
$9.8M
Non-cash interest expense
$808.0K
$419.0K
$1.3M
$832.0K
Non-cash lease expense
$897.0K
$444.0K
$1.3M
$827.0K
Deferred income taxes
$34.4M
$19.2M
$42.5M
$14.8M
Accounts receivable, net
($66.0M)
($59.1M)
($38.5M)
($4.3M)
Prepaid expenses and other current assets
$4.6M
$6.0M
($719.0K)
($471.0K)
Other assets
$138.0K
$121.0K
$347.0K
$284.0K
Accounts payable and accrued expenses
($9.5M)
($4.9M)
$6.5M
($4.2M)
Accrued research and development costs
$22.0K
($1.1M)
($3.8M)
($2.7M)
Operating lease liabilities
($1.3M)
($621.0K)
($1.8M)
($1.2M)
Other liabilities
($528.0K)
($219.0K)
$4.1M
$3.9M
Net cash provided by operating activities
$63.4M
$5.1M
$52.5M
$4.9M
Proceeds from employee stock purchase plan
303.0K
—
94.0K
94.0K
Repayment of 2026 Convertible Notes
($200.0M)
—
—
—
Net cash provided by (used in) financing activities
($199.7M)
—
$94.0K
$94.0K
Effect of exchange rate changes on cash and cash equivalents
($29.0K)
($106.0K)
($680.0K)
($654.0K)
Net increase (decrease) in cash and cash equivalents